4.8 Article

Cu Single Atom Nanozyme Based High-Efficiency Mild Photothermal Therapy through Cellular Metabolic Regulation

期刊

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202209245

关键词

Heat Shock Proteins; Mild Photothermal Therapy; Reactive Oxygen Species; Single Atom Nanozymes; Sodium-Dependent Glucose Transporter

资金

  1. National Key Research and Development Program of China [2022YFB3804500]
  2. National Natural Science Foundation of China [NSFC 52072082, 51929201, 51672268, 51720105015, 51972138, 52250077, 51828202]
  3. Science and Technology Development Planning Project of Jilin Province [20190201232JC, 20210402046GH]
  4. Guangdong Basic and Applied Basic Research Foundation [2019A1515012214]
  5. Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital [202011-105]

向作者/读者索取更多资源

In this study, a polyporous Cu single atom nanozyme loaded with licogliflozin (LIK066) was designed to achieve efficient mild photothermal therapy (PTT) by inhibiting heat shock proteins (HSPs) synthesis and damaging existing HSPs in cancer cells.
Upregulation of heat shock proteins (HSPs) drastically compromises the treatment effect of mild photothermal therapy (PTT). Herein, we designed a polyporous Cu single atom nanozyme (Cu SAzyme) loaded with licogliflozin (LIK066) for HSP-silencing induced mild PTT. On one hand, LIK066 inhibits glucose uptake by shutting sodium-dependent glucose transporter (SGLT) valve, effectively blocking the energy source for adenosine triphosphate (ATP) generation. Without sufficient energy, cancer cells cannot synthesize HSPs. On the other hand, Cu SAzyme presents extraordinary multienzyme activities to induce reactive oxygen species (ROS) storm formation, which can damage the existing HSPs in cancer cells. Through a two-pronged strategy of SGLT inhibitor and ROS storm, LIK066-loaded Cu SAzyme shows high efficiency for comprehensive removal of HSPs to realize mild PTT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据